Brief: Denali Therapeutics and Biogen To Revise Clinical Development Program For BIIB122, Being Developed As Treatment Of Parkinson’s Disease

Denali Therapeutics

05/06/2023 16:15

June 5 (Reuters) - Biogen Inc  BIIB.O :
    * DENALI THERAPEUTICS INC - CO, BIOGEN INC. TO REVISE
CLINICAL
DEVELOPMENT PROGRAM FOR BIIB122, BEING DEVELOPED AS TREATMENT OF
PARKINSON’S DISEASE
    * DENALI THERAPEUTICS INC - PLANNED REVISIONS TO BIIB122
CLINICAL
DEVELOPMENT PROGRAM NOT BASED ON ANY SAFETY OR EFFICACY DATA
FROM STUDIES OF BIIB122
    * DENALI THERAPEUTICS INC - REMAIN COMMITTED TO ADVANCING
THE
DEVELOPMENT OF BIIB122


Further company coverage:  BIIB.O 

 ((Reuters.Briefs@thomsonreuters.com;))